Pharmacoepidemiology is the study of medication utilization, safety and effectiveness of drugs in large numbers of people. It can be called a bridge science spanning both clinical pharmacology and epidemiology. Pharmacoepidemiology often involves the analysis of “big data” using methods of clinical epidemiology and applying them to generate new evidence to improve clinical and policy decision making of medications. Research questions include (but not limited to): understanding beneficial and adverse drug effects of medications, drug utilization, real-world effectiveness, clinical effects of drug-drug interactions, effects of medication non-adherence, impact of policy changes on drug utilization.
Importantly, due to the potential application of many studies and the broad importance of medications and therapies to the healthcare system, work in this field can have a direct impact and inform policies and clinical decision making. We wish to capture a diversity of opinions and experiences across a broad range of areas, from the traditional (drug utilization, drug safety and effectiveness etc.) to the new (big data, AI, new technologies).
The Topic Editors' goal is to consolidate research that shows how pharmacoepidemiologic research can directly influence change in the clinical and policy spheres around the world.
This Research Topic welcomes papers that will provide both theoretical and empirical findings. We encourage submissions that aim to highlight how the research has or will inform pharmaceutical policy or clinical decision-making.
Potential points of interest include, but are not limited to:
• Drug reimbursement and change in spending
• Real-world experiences
• Applications of drug utilization research
• policy evaluations
• Real-world drug safety
• Real-world evidence and its application to the drug life-cycle.
Special interest (but not limited) to these clinical areas:
• Biologics and Biosimilars
• Opioids
• Drugs for rare diseases
• Diabetes treatments
We encourage contributions from health policy-makers, academics, practitioners and consumers, as well as colleagues in other sectors whose work impacts pharmaceutical policy or clinical-decision making. We are interested in how policy and practice changes over time, how it compares across the globe, and how it has informed change. We welcome full research papers, brief reports, systematic reviews, review papers from areas such as health policy, social and health psychology, pharmacoeconomics, pharmaceutical management, public health. Accepted articles must clearly show the potential or actual policy relevance- we suggest this is clear in the abstract. We will not be accepting studies that are limited to only adverse event reports.
Pharmacoepidemiology is the study of medication utilization, safety and effectiveness of drugs in large numbers of people. It can be called a bridge science spanning both clinical pharmacology and epidemiology. Pharmacoepidemiology often involves the analysis of “big data” using methods of clinical epidemiology and applying them to generate new evidence to improve clinical and policy decision making of medications. Research questions include (but not limited to): understanding beneficial and adverse drug effects of medications, drug utilization, real-world effectiveness, clinical effects of drug-drug interactions, effects of medication non-adherence, impact of policy changes on drug utilization.
Importantly, due to the potential application of many studies and the broad importance of medications and therapies to the healthcare system, work in this field can have a direct impact and inform policies and clinical decision making. We wish to capture a diversity of opinions and experiences across a broad range of areas, from the traditional (drug utilization, drug safety and effectiveness etc.) to the new (big data, AI, new technologies).
The Topic Editors' goal is to consolidate research that shows how pharmacoepidemiologic research can directly influence change in the clinical and policy spheres around the world.
This Research Topic welcomes papers that will provide both theoretical and empirical findings. We encourage submissions that aim to highlight how the research has or will inform pharmaceutical policy or clinical decision-making.
Potential points of interest include, but are not limited to:
• Drug reimbursement and change in spending
• Real-world experiences
• Applications of drug utilization research
• policy evaluations
• Real-world drug safety
• Real-world evidence and its application to the drug life-cycle.
Special interest (but not limited) to these clinical areas:
• Biologics and Biosimilars
• Opioids
• Drugs for rare diseases
• Diabetes treatments
We encourage contributions from health policy-makers, academics, practitioners and consumers, as well as colleagues in other sectors whose work impacts pharmaceutical policy or clinical-decision making. We are interested in how policy and practice changes over time, how it compares across the globe, and how it has informed change. We welcome full research papers, brief reports, systematic reviews, review papers from areas such as health policy, social and health psychology, pharmacoeconomics, pharmaceutical management, public health. Accepted articles must clearly show the potential or actual policy relevance- we suggest this is clear in the abstract. We will not be accepting studies that are limited to only adverse event reports.
